Truist Securities Rates Septerna (SEPN) buy, $43 Price Target
Truist Securities reiterates a buy rating on Septerna, Inc. with a target price of $43.0 as the stock trades at $33.49, a 28.40% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Truist Securities rated Septerna, Inc. ($SEPN) "buy" with a $43 price target on July 1, 2026.
Since the rating, $SEPN is up 5.2% after 1 week, down 0.5% after 1 month and up 5.0% to date (from the $34.61 close on Jul 1, 2026).
SEPN
Septerna, Inc.
Key Points
- Truist Securities has reiterated its buy rating on Septerna, Inc. with a target price of $43.0, while the stock currently trades at $33.49.
- Truist Securities's $43 price target implies 28.40% upside from Septerna, Inc.'s ($SEPN) current $33.49 share price.
- The stock has a 52-week range of $15.86 to $51.10, indicating significant volatility and a current position below its high.
- Analysts generally have a strong buy consensus on Septerna, with a mean price target of $54.22 from nine opinions.
Get $SEPN trade alerts by text
We text you when insiders, Congress or big funds trade $SEPN. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Septerna, Inc. alert may contain errors. Disclosures
Truist Securities Maintains Buy Rating
On July 1, 2026, Truist Securities reaffirmed its buy rating on Septerna, Inc. (SEPN) with a target price of $43.0. The stock is currently trading at $33.49, which suggests a potential upside for investors. This action reflects the firm’s confidence in the company’s prospects as it develops innovative therapies in the biotechnology sector.
Truist Securities vs. the S&P 500
Hypothetical returns from Truist Securities's disclosed trades, not real profit or advice. How we model this.
Analysts Set New Price Targets
Truist's reiteration comes amid a backdrop of positive sentiment from other analysts. On the same day, Guggenheim maintained its buy rating with a target of $45.0, while HC Wainwright also reiterated a buy rating with a target of $40.0. JP Morgan recently maintained an Overweight rating with a target of $48.0, demonstrating strong support for Septerna among analysts. The average target price from nine analysts is $54.22, indicating significant upside potential from current levels.
Stock Performance and Implications
Septerna’s stock is currently trading significantly below its 52-week high of $51.10. With the current price at $33.49, the stock has room to grow, particularly as analysts set higher price targets. The stock’s performance has shown volatility, reflecting the market's reaction to its clinical-stage developments and revenue growth.
$SEPN price target
Septerna, Inc. daily closes and this analyst's $43 target. Not advice.
Recent Earnings
For the year ended December 31, 2025, Septerna reported revenue of approximately $98.9 million, representing a remarkable growth of 223.8% compared to the previous year. The company's net margin stood at -24.5%, and it recorded an EPS of -0.53. The next earnings report is set for November 9, 2026, which could provide further insights into its financial health and operational progress.
Insider Buying and Selling at Septerna, Inc.
Insider trading activity at Septerna has been notable. On June 26, 2026, several insiders purchased shares, including Shalini Sharp, L.P. Ra Capital Management, Alan Ezekowitz, and Bernard Coulie, each acquiring 15,000 shares. This insider buying suggests a level of confidence in the company's future performance, although the exact price and value for these transactions were not disclosed.
What Septerna, Inc. Does
Septerna, Inc. is a clinical-stage biotechnology firm based in South San Francisco, California. The company focuses on developing oral small molecule products targeting various diseases, including endocrinology and immunology. Its work on G protein-coupled receptor (GPCR) therapies positions it as an innovative player in the biotech space.
What's Ahead for Septerna, Inc.
Investors will be watching the upcoming earnings report on November 9, 2026, for updates on revenue growth and other financial metrics. As of now, the positive analyst sentiment and insider buying activity may indicate a favorable outlook for Septerna as it continues to advance its clinical programs. Remember, the 13F filings reflect past positions and may not represent current holdings.
Related Filing Alerts
Source: Truist Securities's rating change on $SEPN (Jul 1, 2026). Written by software, not financial advice. How we make alerts